GE HealthCare debuts Allia Celeo with automated imaging adjustments and CE marking

GE HealthCare introduced Allia Celeo, which includes automated imaging adjustments.

GE HealthCare introduced Allia Celeo on November 1 at TCT 2026. The ceiling-mounted system is designed for image-guided interventions. GE describes an imaging function that automatically adjusts the balance between image quality and radiation dose in real time for two-dimensional and three-dimensional imaging. The company says the system is CE marked, that its U.S. 510(k) submission is pending and that it is unavailable for sale in the United States. [GE HealthCare product announcement](https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-debuts-allia-celeo-ceiling-mounted-interventional)

Where automation fits during a procedure

Imaging can help a clinical team see instruments and anatomy as a procedure proceeds. The manufacturer positions its automatic adjustment feature as one part of that process. The press release also lists compatible applications for purposes including embolization planning, roadmapping and needle guidance. It says applications may be sold separately and may vary by market. An institution therefore needs to check the precise hardware and software combination available where it operates. [GE HealthCare configuration details](https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-debuts-allia-celeo-ceiling-mounted-interventional)

A department evaluating the equipment would want evidence on the kinds of procedures it performs and on how staff can see or adjust the imaging settings. A usable image and a lower dose are related goals with different measurements. A feature that adjusts settings during a procedure should be assessed on both, including cases where the operator needs to intervene.

Product clearance and clinical evidence answer different questions

GE's announcement gives the regulatory status of the system by market and describes intended capabilities. It does not establish that every related software application has the same availability, or show how the new system changes patient outcomes across different clinical settings. A purchasing team would need to inspect the documentation for the marketed configuration and the evidence applicable to its procedures.

The debut makes Allia Celeo a new option in CE-marked markets where it is offered. The U.S. status described by GE is a pending clearance process. [GE HealthCare regulatory notes](https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-debuts-allia-celeo-ceiling-mounted-interventional)